164 related articles for article (PubMed ID: 11750569)
1. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression.
Risaliti A; Baccarani U; Vianello V; Donini A; Adani GL; Sainz M; Montanaro D; Alessandrini V; Bresadola F
Transplant Proc; 2001; 33(7-8):3684-5. PubMed ID: 11750569
[No Abstract] [Full Text] [Related]
2. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients.
Rabkin JM; Rosen HR; Corless CL; Olyaei AJ
Transplant Proc; 2002 Aug; 34(5):1557-8. PubMed ID: 12176483
[No Abstract] [Full Text] [Related]
3. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.
Klupp J; Glanemann M; Bechstein WO; Platz KP; Langrehr JM; Keck H; Settmacher U; Radtke C; Neuhaus R; Neuhaus P
Transplant Proc; 1999; 31(1-2):1113-4. PubMed ID: 10083497
[No Abstract] [Full Text] [Related]
4. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
[TBL] [Abstract][Full Text] [Related]
5. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
[TBL] [Abstract][Full Text] [Related]
6. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation.
Bilbao I; Pou L; Allende E; Lázaro JL; Charco R; Hidalgo E; Margarit C
Transplant Proc; 2001 May; 33(3):2124-6. PubMed ID: 11377472
[No Abstract] [Full Text] [Related]
7. Neoral is superior to FK 506 in liver transplantation.
Levy GA
Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
[No Abstract] [Full Text] [Related]
8. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation.
Ben-Ari Z; Mor E; Bar-Nathan N; Shaharabani E; Shapira Z; Tur-Kaspa R
Transplant Proc; 2003 Mar; 35(2):612-3. PubMed ID: 12644067
[No Abstract] [Full Text] [Related]
9. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation.
Rafecas A; Lladó L; Albiol MT; Ramos E; Torras J; Fabregat J; Lama C; Busquets J; Ibáñez L; Figueras J; Jaurrieta E
Transplant Proc; 2002 Feb; 34(1):107. PubMed ID: 11959209
[No Abstract] [Full Text] [Related]
10. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation.
Gridelli B; Colledan M; Lucianetti A; Ulla L; Riva S; Segalin A; Fassati LR; Torre G
Transplant Proc; 1998 Aug; 30(5):1861-2. PubMed ID: 9723311
[No Abstract] [Full Text] [Related]
11. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus.
Hernández D; Alvarez A; Torres A; Oppenheimer F; Cobo M; González-Posada J; Jiménez A; Lorenzo V; Torregrosa V
Transplant Proc; 2003 Aug; 35(5):1727-9. PubMed ID: 12962773
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factors and immunosuppressive regimen after liver transplantation.
Rossetto A; Bitetto D; Bresadola V; Lorenzin D; Baccarani U; De Anna D; Bresadola F; Adani GL
Transplant Proc; 2010 Sep; 42(7):2576-8. PubMed ID: 20832547
[TBL] [Abstract][Full Text] [Related]
13. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation.
Cai TH; Esterl RM; Nichols L; Cigarroa F; Speeg KV; Halff GA
Transplant Proc; 1998 Jun; 30(4):1413-4. PubMed ID: 9636572
[No Abstract] [Full Text] [Related]
14. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation.
Jonas S; Guckelberger O; Bechstein WO; Berg T; Müller AR; Platz KP; Tullius SG; Settmacher U; Steinmüller T; Hopf U; Neuhaus P
Transplant Proc; 1998 Aug; 30(5):2179-81. PubMed ID: 9723433
[No Abstract] [Full Text] [Related]
15. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
[No Abstract] [Full Text] [Related]
16. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation.
Zervos XA; Weppler D; Fragulidis GP; Torres MB; Nery JR; Khan MF; Pinna AD; Kato T; Miller J; Reddy KR; Tzakis AG
Transplantation; 1998 Apr; 65(8):1044-6. PubMed ID: 9583863
[TBL] [Abstract][Full Text] [Related]
17. Conversion from tacrolimus to Neoral in liver and kidney transplant recipients.
Ott R; Bussenius-Kammerer M; Scholz D; Neuhaus R; Tolba RH; Fricke L; Müller V
Transplant Proc; 2001; 33(7-8):3166-8. PubMed ID: 11750359
[No Abstract] [Full Text] [Related]
18. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy.
Varo E; Padin E; Otero E; Tomé S; Castroagudin JF; Delgado M; Conde R; Segade FR; Mella C; González-Quintela A
Transplant Proc; 2002 Aug; 34(5):1553-4. PubMed ID: 12176481
[No Abstract] [Full Text] [Related]
19. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation.
Andrews WS; Sommerauer J; Conlin C; Moore P
Transplant Proc; 1996 Apr; 28(2):897-8. PubMed ID: 8623452
[No Abstract] [Full Text] [Related]
20. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine.
Zajicek A; Esquivel C; Millan M; Cox K; Berquist R; Berquist W
Transplant Proc; 2002 Aug; 34(5):1976-8. PubMed ID: 12176653
[No Abstract] [Full Text] [Related]
[Next] [New Search]
